July 27, 2020 Revised

Piramal Enterprises Limited: Ratings reaffirmed

Summary of rating action

Instrument*	Previous Rated Amount (Rs. crore)	Current Rated Amount (Rs. crore)	Rating Action
Commercial Paper	9,000.0	-	[ICRA] A1+; reaffirmed and withdrawn
Long Term/Short Term Fund Based	300.0	300.0	[ICRA] AA (negative) /[ICRA] A1+; reaffirmed
Long Term- Fund Based Term Loan	1,350.0	1,350.0	[ICRA] AA (negative); reaffirmed
Long Term- Fund Based Term Loan	1,145.0	-	[ICRA] AA (negative); reaffirmed and withdrawn
Short Term Non-Fund Based	200.0	200.0	[ICRA] A1+; reaffirmed
Short Term Fund based	1,620.0	1,620.0	[ICRA] A1+ reaffirmed
Short Term Fund based	500.0	-	[ICRA] A1+ reaffirmed and withdrawn
No Convertible Debentures	6260.0	-	[ICRA] AA (negative); reaffirmed and withdrawn
No Convertible Debentures	7,840.0	7840.0	[ICRA] AA (negative); reaffirmed
Long Term Principal Protected Market Linked Debentures	330.0	-	PP-MLD [ICRA] AA (negative); reaffirmed and withdrawn
Long Term Principal Protected Market Linked Debentures	170.0	-	Provisional PP-MLD [ICRA] AA (negative); reaffirmed and withdrawn
Total	**28,715.0**	**11,310.0**	

**Instrument details are provided in Annexure-1*

The PP-MLD rating is provisional (as denoted by the prefix 'Provisional' before the rating symbol) and is subject to fulfilment and review of all pending documentation pertaining to the facility rated by ICRA.

According to the terms of rated market-linked debentures, the principal amount is protected against erosion while the returns on the investment could vary, being linked to movements in one or more variables, such as equity/equity indices, commodity prices, sovereign debt securities and/or foreign exchange rates. The rating assigned expresses ICRA's current opinion on the credit risk associated with the issuer concerned. The rating does not address the risks associated with variability in returns resulting from adverse movements in the variable(s) concerned.

Rationale

ICRA has withdrawn the ratings assigned to Piramal Enterprises Limited's (PEL's) Rs. 6,260.0 crore NCD programme, Rs. 9,000.0 crore commercial paper programme, Rs. 500.0 crore PP-MLD programme, Rs. 1,145.0 crore long-term fund-based limits and Rs. 500.0 crore short-term fund-based limits as no amount is outstanding against these rated instruments. The ratings were withdrawn at the request of the company and as per ICRA's policy on the withdrawal and suspension of credit ratings.

The ratings factor in the strength derived from an established track record of the promoter group in building and scaling successful businesses led by a strong and experienced management team. The company demonstrated financial flexibility in the past few months by raising sizeable funds through rights issue, issue of compulsory convertible debentures (CCDs), divestments, sale of healthcare insights and analytics (HIA) business and refinancing debt. The ratings favorably factor in the established position and wide product portfolio of PEL in the global pharmaceutical business coupled with its geographical diversification. The company has successfully cleared multiple regulatory and customer audits over the years including United States Food and Drug Association (USFDA). PEL's integrated contract manufacturing capabilities of active pharmaceutical ingredients (APIs), high potent APIs and formulations at its accredited manufacturing facilities provides high client retention and business stickiness. It also has a portfolio of differentiated and niche pharmaceutical complex generics care products like anesthetics that include inhalation and injectable anesthesia, pain management drugs and intrathecal spasticity management opioids. PEL acquired a high margin product portfolio from Janssen Pharmaceuticals (October 2016) and Mallinckrodt LLC (March 2017) to strengthen its Complex generics portfolio. PEL is also one of the established players in the domestic Indian consumer health products (over the counter, OTC) segment with over 20 popular brands and a pan India distribution network.

The pharmaceutical business EBIDTA margins have increased from 18% in FY2018 and 21% in FY2019 to 26% in FY2020, led by synergies from acquisitions of high margin products, better sales realisations over the years, healthy capacity utilizations, backward integration of raw materials and an efficient distribution network. The pharmaceutical business generated a healthy RoCE of 15-16% in FY2020. However, the overall RoCE remains depressed to single digits on account of non-yielding investments in the Shriram Group as well as other corporate overheads.

The credit profile of PEL has been supported by significant funds raised through a mix of asset & stake sale, and equity raise. The company raised Rs. 14,500.0 crore in FY2020, of which Rs. 3,650.0 crore was raised through rights equity issue in January 2020, Rs. 1,750.0 crore through CCDs in December 2019, Rs. 2,300 crore through sale of Shriram Transport Finance Company investments in June 2019 and Rs. 6,750.0 crore through divestment of its HIA vertical in February 2020. Further, in June 2020, the company announced divestment of 20% minority stake in its Pharmaceuticals business (to be housed under separate subsidiary) to Carlyle Group for ~Rs. 3,400.0 crore ($490 million). The proceeds for these fund-raising activities were used to deleverage PEL. The total debt at PEL, on a standalone basis (legal entity), has reduced to Rs. 10,618.32 crore as on March 31, 2020 from Rs. 17,487.5 crore as on March 31, 2019. PEL infused approximately Rs. 3,700.0 crore as equity for its financial service business, while incremental loans and advances stood at approximately Rs. 2,000.0 crore in FY2020.

PEL has successfully refinanced some of the loans in its NBFC subsidiaries to longer tenures, albeit at a higher cost. This was undertaken amid a challenging operating environment, tight liquidity conditions and risk aversion towards non-banking financial institutions, particularly wholesale oriented financiers. The Group also holds a 10% stake in Shriram City Union Finance Limited (SCUF, listed), and 20% stake in Shriram Capital which can be divested to further raise liquidity apart from diluting equity in its various businesses such as financial services and pharmaceuticals. Overall, ICRA takes comfort from the Group's track record of raising funds and refinancing ability.

The Negative outlook on the rating stems from the possibility of higher than expected funding support, which may be required for its financial services business as a result of the Covid-19 impact. This may lead to deterioration in the credit profile of PEL on standalone basis. The financial service business majority lending is to the real estate sector (~74% of the loan book), which has an inherently high-risk profile. The operating environment for non-banks, particularly wholesale/real estate financiers, has been challenging over the past six quarters, with increased risk perception of the sector by investors limiting the financial flexibility of most non-banks. The Covid-19 pandemic and the resulting nationwide lockdown further impacted the sale of real estate players. ICRA notes that the company has hitherto maintained a healthy asset quality, despite the deterioration in FY2020 with gross non-performing assets (GNPA) increasing to 2.4% of the loan book as on March 31, 2020 from 0.9% of the loan book as on March 31, 2019. Further, PEL's financial services business has raised funds by down selling some of the assets in its portfolio, which is expected to be the focus in the near term to shore up liquidity and reduce any portfolio concentration risk. Going forward, the ability of PEL's financial services to achieve timely exits and or refinance real estate exposures would remain important for maintaining asset quality.

While the Group demonstrated its ability to successfully raise funds in the current challenging scenario, maintaining adequate liquidity to cover debt repayments maturing over the next three to six months remains critical. On a consolidated basis, the Group has considerable cash outflows primarily towards debt repayment pertaining to the financial services business. The Group intends to meet the debt repayments by borrowing long term funds, down-selling and or refinancing of financial services assets and pharmaceutical stake sale inflow and also maintain ample liquidity cover. ICRA expects PEL to support the financial services business in case of any liquidity mismatches.

Key rating drivers and their description

Credit strengths

Strong position for the pharmaceutical business including accredited manufacturing facilities – PEL has 14 global manufacturing facilities for its contract development and manufacturing operations (CDMO) and complex hospital generics with a large global distribution network spanning 100 countries. The revenues are geographically diversified with ~61% of its revenues coming from USA and Europe. The contract manufacturing business has strong capabilities in high potent APIs (HPAPI) and antibody drug conjugates (ADCs), injectables and hormonal products and offers integrated solutions from discovering to manufacturing APIs, HPAPIs and formulations as a strategic solution partner for its clients. The complex hospital generics business has high entry barriers as they are complex in terms of manufacturing, selling and distribution, resulting in limited competition. It caters to niche segments like anesthetics that include inhalation and injectable anesthesia, pain management drugs and intrathecal spasticity management opioids, while being a global player in the inhalation anesthetics segment. PEL has a strong and clean track record of approvals by leading international agencies such as USFDA and marquee clients with expanding presence in high margin products. PEL's Indian consumer products consist of more than 20 major brands in pharmaceutical, personal care, vitamins and nutrition, dermatological and antacids, analgesics and baby care. In the OTC segment, PEL has expanded its distribution reach to more than 1,500 towns with an outlet presence of more than 2.8 lakh, a chemist outreach of 1.6 lakh and a total dedicated field force of 1,700 individuals.

Improvement in profitability for pharmaceutical business and fund-raising initiatives led to moderation in credit metrics – PEL's pharmaceutical vertical has shown increased profitability in the past few years. The pharmaceutical business EBIDTA margins increased from 18% in FY2018 and 21% in FY2019 to 26% in FY2020 led by synergies from acquisitions of high margin products and niche manufacturing facilities, better sales realisations over the years, healthy capacity utilizations, backward integration of raw materials and a global distribution network. The business profitability is supported by the company's integrated CDMO vertical, resulting in client retention and its entrenched portfolio in complex hospital generics. In the past, PEL acquired a selected portfolio of Janssen Pharmaceuticals (October 2016) and Mallincrodt LLC (March 2017) covering sterile products for controlled substances and pain management drugs along with various manufacturing facilities for its CDMO business. The pharmaceutical business generated a RoCE of 15-16% in FY2020. The overall RoCE for PEL consolidated (Ex-financial services businesses) remains low on account of investments in non-yielding Shriram Group investments and corporate overheads. Further, PEL raised approximately Rs. 14,500 crore during FY2020 coupled with 20% minority stake sale in its pharmaceutical vertical for Rs. 3400 crore ($490 million, announced in June 2020 and transaction to be concluded by December 2020) which will significantly deleverage the company at a standalone level. The total debt levels for PEL on a standalone basis (legal entity) reduced to Rs. 10,618.32 as on March 31, 2020 from Rs. 17,487.5 crore as on March 31, 2019.

Financial flexibility arising from its stake in various businesses, including Shriram Group investments, refinancing and capital raising capabilities – The credit profile of PEL has been supported by significant funds raised through a mix of asset & stake sale and equity raise. The company raised Rs. 14,500.0 crore in FY2020, of which Rs. 3,650.0 crore was raised through rights equity issue in January 2020, Rs. 1,750.0 crore through CCDs in December 2019, Rs. 2,300 crore through sale of Shriram Transport Finance Company investments in June 2019 and Rs. 6,750.0 crore through divestment of its HIA vertical in February 2020.

PEL has successfully refinanced some of the loans in its NBFC subsidiaries to longer tenures, albeit at a higher cost. This was undertaken amid a challenging operating environment, tight liquidity conditions and risk aversion towards non-banking financial institutions, particularly wholesale oriented financiers. The Group also holds a 10% stake in Shriram City Union Finance Limited (SCUF, listed) and 20% stake in Shriram Capital which can be divested to further raise liquidity, apart from diluting equity in its various businesses such as financial services and pharmaceuticals. Overall, ICRA takes comfort from the Group's track record of raising funds and refinancing ability.

Credit challenges

Higher than expected funding support for financial services business – The financial service business is focused on lending to the real estate sector (~74% of the loan book), which has an inherently high-risk profile. The operating environment for non-banks, particularly wholesale/real estate financiers, has been challenging over the past six quarters, with increased risk perception of the sector by the investors, limiting the financial flexibility of most non-banks. The resulting slowdown in disbursements by these non-banks has constrained the funding access for the real estate sector (especially residential), which has already been facing prolonged slowdown due to subdued sales. The Covid-19 pandemic and the resulting nationwide lockdown further impacted the sale of residential units. The pandemic also impacted the commercial and retail real estate segments. While the near-term pressure on the developers was mitigated by the moratorium offered for their loan instalments under the Covid-19 regulatory package announced by the Reserve Bank of India (RBI), a slow pick up in sale will impact the cash flows of the developers over the medium term. This is expected to heighten the vulnerability of PEL's financial services portfolio and pose greater challenges in maintaining asset quality. ICRA notes that the company has hitherto maintained a healthy asset quality, despite the deterioration in FY2020 with gross non-performing assets (GNPA) increasing to 2.4% of the loan book as on March 31, 2020 from 0.9% of the loan book as on March 31, 2019. Further, PEL's financial services business has raised funds by down selling some of the assets in its portfolio, which is expected to be the focus in the near term to shore up liquidity and reduce any portfolio concentration risk. Going forward, the ability of PEL's financial services to achieve timely exits and or refinance real estate exposures would remain important for maintaining asset quality. The Negative outlook on the rating stems from the possibility of higher than expected funding support, which may be required for its financial services business as a result of the Covid-19 impact

Maintaining adequate liquidity in view of debt repayments and refinancing requirements for financial services business – While the Group has demonstrated its ability to successfully raise funds, including rights issue, refinancing of bank loans, and divestments of businesses to reduce debt levels and infuse equity into the business, in the current scenario, maintaining adequate liquidity to cover debt repayments remains critical. On a consolidated basis, the Group has considerable cash outflows primarily towards debt repayment pertaining to the financial services business. The Group intends to meet the debt repayments by borrowing long term funds, down-selling and or refinancing of financial services assets and pharmaceutical stake sale inflow and also maintain ample liquidity cover. ICRA expects PEL to support the financial services business in case of any liquidity mismatches.

Liquidity position: Adequate

The company's liquidity position remains supported by its strong promoter group, past track record of successfully raising capital and refinancing debt repayments coupled with expected infusion from stake sale of the pharmaceutical business. Further, PEL's status as the holding company of Piramal Capital and Housing Finance Limited (PCHFL) and its pharmaceutical business (to be demerged in a separate subsidiary) provides it with financial flexibility to raise funds through equity dilution.

Rating sensitivities

Positive triggers – An upgrade is unlikely in the near term given that the rating is on a Negative outlook. ICRA could revise the outlook to Stable from Negative in case of planned execution of the pharmaceutical stake sale and if there is a sustained improvement in mobilisation of long-term funds from diverse sources for its financial services businesses leading to lower dependence on PEL.

Negative triggers – The ratings will be downgraded in the event of lower than expected performance of the financial services business including provisioning for bad debts. The ratings will also be negatively impacted owing to large size debt funded capex outlay or acquisitions.

Analytical approach

Analytical Approach	Comments
Applicable Rating Methodologies	[Corporate Credit Rating Methodology]
Parent/Group Support	Not Applicable
Consolidation/Standalone	For arriving at the ratings, ICRA has analysed the standalone credit profile of PEL, including the Pharma business as well as the Shriram Group investments. Further, ICRA has factored-in the ordinary and extraordinary funding support required for the financial services business. ICRA may modify its rating approach, if required, upon conclusion of Pharma stake sale based upon the exact contours of the deal.

About the company

PEL is one of India's largest diversified companies, with an established presence across pharmaceuticals (CDMO, complex hospital generics and consumer healthcare products) and financial services. In FY2020, PEL divested its stake in the HIA business to Clarivate Analytics PLC for $950 million. It integrated its pharmaceuticals manufacturing capabilities across 14 global facilities for APIs, HPAPIs and formulations, as well as a global distribution network in over 100 countries. PEL sells a portfolio of niche differentiated pharma products that include inhalation and injectable anesthesia, pain management drugs and intrathecal spasticity management opioids (top global provider of inhalation anesthetics). The company is also strengthening its presence in the consumer healthcare segment (OTC) with its well renowned brand portfolio of more than 20 major brands. In June 2020, the Carlyle Group bought 20% minority stake in PEL's pharmaceutical business for $490 million.

PCHFL (rated [ICRA] AA/Negative/A1+) is registered as a housing finance company with the National Housing Bank (NHB) and is engaged in various financial services businesses. It provides real estate lending, housing finance, corporate finance lending and small and emerging corporate lending. PEL is also planning to foray into the consumer financing business, which is expected to consist of secured products like small commercial vehicles and multi collateral secured loans.

The company also has strategic alliances with top global funds such as APG Asset Management, Bain Capital Credit, CDPQ and Ivanhoé Cambridge. PEL has long-term equity investments in the Shriram Group, a leading financial conglomerate in India.

Key financial indicators (standalone)

	FY2019 Audited	FY2020 Audited
Operating Income (Rs. crore)	3867.4	3849.0
PAT (Rs. crore)	-868.0	144.8
OPBDIT/OI (%)	48.3%	35.2%
PAT/OI (%)	-22.4%	3.8%
Total Outside Liabilities/Tangible Net Worth (times)	0.9	0.5
Total Debt/OPBDIT (times)	9.4	7.8
Interest Coverage (times)	1.2	0.8

Status of non-cooperation with previous CRA: Not applicable

Any other information: None

Rating history for past three years

Instrument	Type	Amount Rated (Rs. crore)	Amount Outstanding (Rs. crore)	Current Rating (FY2021)		Chronology of Rating History for the Past 3 Years								
				Date & Rating in FY2021		Date & Rating in FY2020		Date & Rating in FY2019					Date & Rating in FY2018	
				Jul 27, 2020	May 28, 2020	Jun 25, 2019	Apr 22, 2019	Feb 15, 2019	Dec 31, 2018	Dec 21, 2018	Nov 26, 2018	Apr 05, 2018	Oct 09, 2017	Jun 05, 2017
Fund based	Long-term/ Short-term	300.0	208.0	[ICRA] AA (Negative)/ [ICRA] A1+	[ICRA] AA (Negative)/ [ICRA] A1+	[ICRA] AA (Negative)/ [ICRA] A1+ outstanding	[ICRA] AA (negative)/ [ICRA] A1+	[ICRA] AA (stable)/ [ICRA] A1+	[ICRA] AA (stable)/ [ICRA] A1+	[ICRA] AA (stable)/ [ICRA] A1+	[ICRA] AA (stable)/ [ICRA] A1+	[ICRA] AA (stable)/ [ICRA] A1+	[ICRA] AA (stable)/ [ICRA] A1+	[ICRA] AA (stable)/ [ICRA] A1+
Term Loan	Long term	1350	875.0	[ICRA] AA (Negative)	[ICRA] AA (Negative)	[ICRA] AA (Negative) Outstanding	[ICRA] AA (negative)	[ICRA] AA (stable)	[ICRA] AA (stable)	[ICRA] AA (stable)	[ICRA] AA (stable)	[ICRA] AA (stable)	[ICRA] AA (stable)	[ICRA] AA (stable)
Term Loan	Long term	1145	-	[ICRA] AA (Negative); withdrawn	[ICRA] AA (Negative)	[ICRA] AA (Negative) Outstanding	[ICRA] AA (negative)	[ICRA] AA (stable)	[ICRA] AA (stable)	[ICRA] AA (stable)	[ICRA] AA (stable)	[ICRA] AA (stable)	[ICRA] AA (stable)	[ICRA] AA (stable)
NCD	Long-term	7840	1335.3	[ICRA] AA (Negative)	[ICRA] AA (Negative)	[ICRA] AA (Negative) Outstanding	[ICRA] AA (negative)	[ICRA] AA (stable)	[ICRA] AA (stable)	[ICRA] AA (stable)	[ICRA] AA (stable)	[ICRA] AA (stable)	[ICRA] AA (stable)	[ICRA] AA (stable)
NCD	Long-term	6260	-	[ICRA] AA (Negative); withdrawn	[ICRA] AA (Negative)	[ICRA] AA (Negative) Outstanding	[ICRA] AA (negative)	[ICRA] AA (stable)	[ICRA] AA (stable)	[ICRA] AA (stable)	[ICRA] AA (stable)	[ICRA] AA (stable)	[ICRA] AA (stable)	[ICRA] AA (stable)
Non-fund based	Short-term	200.0	66.9	[ICRA] A1+	[ICRA] A1+	[ICRA] A1+ Outstanding	[ICRA] A1+	[ICRA] A1+	[ICRA] A1+	[ICRA] A1+	[ICRA] A1+	[ICRA] A1+	[ICRA] A1+	[ICRA] A1+
Fund-based facility	Short-term	1620	800.0	[ICRA] A1+	[ICRA] A1+	[ICRA] A1+ Outstanding	[ICRA] A1+	[ICRA] A1+	[ICRA] A1+	[ICRA] A1+	[ICRA] A1+	[ICRA] A1+	[ICRA] A1+	[ICRA] A1+
Fund-based facility	Short-term	500	-	[ICRA] A1+; withdrawn	[ICRA] A1+	[ICRA] A1+ Outstanding	[ICRA] A1+	[ICRA] A1+	[ICRA] A1+	[ICRA] A1+	[ICRA] A1+	[ICRA] A1+	[ICRA] A1+	[ICRA] A1+
Commercial paper	Short Term	9000	-	[ICRA] A1+; withdrawn	[ICRA] A1+	[ICRA] A1+ Outstanding	[ICRA] A1+	[ICRA] A1+	[ICRA] A1+	[ICRA] A1+	[ICRA] A1+	[ICRA] A1+	[ICRA] A1+	[ICRA] A1+
Principal Protected Market Linked Debentures	Long-term	330	-	PP-MLD [ICRA] AA (Negative); withdrawn	PP-MLD [ICRA] AA (Negative)	PP-MLD [ICRA] AA (Negative) outstanding	PP-MLD [ICRA] AA (negative)	PP-MLD [ICRA] AA (stable)	PP-MLD [ICRA] AA (stable)	-	-	-	-	-

Instrument	Type	Amount Rated (Rs. crore)	Amount Outstanding (Rs. crore)	Current Rating (FY2021)		Chronology of Rating History for the Past 3 Years								
				Date & Rating in FY2021		Date & Rating in FY2020		Date & Rating in FY2019					Date & Rating in FY2018	
				Jul 27, 2020	May 28, 2020	Jun 25, 2019	Apr 22, 2019	Feb 15, 2019	Dec 31, 2018	Dec 21, 2018	Nov 26, 2018	Apr 05, 2018	Oct 09, 2017	Jun 05, 2017
Provisional Principal Protected Market Linked Debentures	Long-term	170	-	Provisional PP-MLD [ICRA] AA (Negative); withdrawn	Provisional PP-MLD [ICRA] AA (Negative)	Provisional PP-MLD [ICRA] AA (Negative) outstanding	Provisional PP-MLD [ICRA] AA (negative)	Provisional PP-MLD [ICRA] AA (stable)	Provisional PP-MLD [ICRA] AA (stable)	-	-	-	-	-

Complexity level of the rated instrument

ICRA has classified various instruments based on their complexity as "Simple", "Complex" and "Highly Complex". The classification of instruments according to their complexity levels is available on the website click here

Annexure-1: Instrument details

ISIN No	Instrument Name	Date of Issuance / Sanction	Coupon Rate	Maturity Date	Amount Rated (Rs. crore)	Current Rating and Outlook
NA	Term Loan 1	16-Aug-17		-	100.00	[ICRA] AA/Negative
NA	Term Loan 2	31-Jul-17		28-Dec-20	500.00	[ICRA] AA/Negative
NA	Term Loan 3	27-Sep-17		-	150.00	[ICRA] AA/Negative
NA	Term Loan 4	19-Sep-17		-	100.00	[ICRA] AA/Negative
NA	Term Loan 5	27-Sep-18		25-Sep-20	500.00	[ICRA] AA/Negative
NA	Line of credit/ST Loan	20-Mar-17		-	500.00	[ICRA] A1+
NA	Line of credit/ST Loan	17-Jan-17		-	300.00	[ICRA] A1+
NA	Line of credit/ST Loan	29-Aug-17		-	135.00	[ICRA] A1+
NA	Line of credit/ST Loan	15-Mar-15		-	100.00	[ICRA] A1+
NA	Line of credit/ST Loan	30-Mar-12		-	135.00	[ICRA] A1+
NA	Line of credit/ST Loan	28-Oct-15		-	100.00	[ICRA] A1+
NA	Line of credit/ST Loan	20-May-16		-	100.00	[ICRA] A1+
NA	Line of credit/ST Loan	7-Dec-17		-	250.00	[ICRA] A1+
NA	Fund Based	NA	NA	NA	300.00	[ICRA] AA/Negative/ A1+
NA	Non- Fund Based	NA	NA	NA	200.00	[ICRA] A1+
INE140A07179	NCD	14-Jul-16	9.75%	14-Jul-26	35.00	[ICRA] AA/Negative
INE140A07203	NCD	19-Jul-16	9.57%	19-Jul-21	10.00	[ICRA] AA/Negative
INE140A07211	NCD	19-Jul-16	9.75%	17-Jul-26	5.00	[ICRA] AA/Negative
INE140A08SW7	NCD	23-Jun-17	8.20%	27-Jul-20	125.00	[ICRA] AA/Negative
INE140A07377	NCD	11-Aug-17	7.90%	11-Aug-20	100.00	[ICRA] AA/Negative
INE140A07385	NCD	14-Sep-17	7.90%	14-Sep-20	330.00	[ICRA] AA/Negative
INE140A07427	NCD	22-Nov-18	9.70%	20-Nov-20	900.00	[ICRA] AA/Negative
INE140A07476	NCD	24-Dec-18	9.70%	24-Dec-20	500.00	[ICRA] AA/Negative
INE140A07419	NCD	22-Nov-18	9.30%	22-Nov-19	100.00	[ICRA] AA/Negative
NA	NCD	Not issued	Not issued	Not issued	5735.00	[ICRA] AA/Negative
NA	PP-MLD	NA	NA	NA	180.00	PP-MLD [ICRA] AA/ Negative; withdrawn
NA	Provisional PP-MLD	NA	NA	NA	170.00	Provisional PP-MLD [ICRA] AA/Negative; withdrawn
NA	Term Loan	NA	NA	NA	1145.00	[ICRA] AA/Negative; withdrawn
NA	Line of credit/ST Loan	NA	NA	NA	500.00	[ICRA] A1+; withdrawn
NA	Commercial Paper	NA	NA	NA	9000.00	[ICRA] A1+; withdrawn
INE140A07120	NCD	1-Mar-16	9.40%	28-Feb-19	50.00	[ICRA] AA/Negative; withdrawn
INE140A07161	NCD	23-Jun-16	9.57%	21-Jun-19	65.00	[ICRA] AA/Negative; withdrawn
INE140A07187	NCD	18-Jul-16	9.45%	15-Jul-19	50.00	[ICRA] AA/Negative; withdrawn
INE140A07229	NCD	20-Jul-16	9.45%	5-Jun-19	150.00	[ICRA] AA/Negative; withdrawn

ISIN No	Instrument Name	Date of Issuance / Sanction	Coupon Rate	Maturity Date	Amount Rated (Rs. crore)	Current Rating and Outlook
INE140A07237	NCD	20-Jul-16	9.45%	15-Jul-19	150.00	[ICRA] AA/Negative; withdrawn
INE140A07252	NCD	29-Jul-16	9.38%	29-Jul-19	200.00	[ICRA] AA/Negative; withdrawn
INE140A07260	NCD	29-Jul-16	9.38%	12-Aug-19	15.00	[ICRA] AA/Negative; withdrawn
INE140A07302	NCD	18-Aug-16	9.264%	15-Apr-19	100.00	[ICRA] AA/Negative; withdrawn
INE140A07310	NCD	25-Aug-16	9.267%	15-Apr-19	10.00	[ICRA] AA/Negative; withdrawn
INE140A07328	NCD	26-Aug-16	9.267%	15-Apr-19	20.00	[ICRA] AA/Negative; withdrawn
INE140A07344	NCD	15-Jun-17	8.15%	14-Jun-19	560.00	[ICRA] AA/Negative; withdrawn
INE140A07351	NCD	20-Jun-17	8.13%	20-Jun-19	600.00	[ICRA] AA/Negative; withdrawn
INE140A07369	NCD	27-Jun-17	8.13%	27-Jun-19	500.00	[ICRA] AA/Negative; withdrawn
INE140A07393	NCD	15-Sep-17	7.60%	15-Mar-19	200.00	[ICRA] AA/Negative; withdrawn
INE140A07401	NCD	16-Nov-18	9.00%	15-May-20	500.00	[ICRA] AA/Negative; withdrawn
INE140A07435	NCD	29-Nov-18	9.00%	29-May-20	500.00	[ICRA] AA/Negative; withdrawn
INE140A07443	NCD	24-Dec-18	9.50%	30-Dec-19	1250.00	[ICRA] AA/Negative; withdrawn
INE140A07450	NCD	24-Dec-18	9.50%	31-Dec-19	250.00	[ICRA] AA/Negative; withdrawn
INE140A07468	NCD	24-Dec-18	9.50%	27-Dec-19	500.00	[ICRA] AA/Negative; withdrawn
INE140A07484*	NCD	28-Dec-18	9.70%	28-Dec-21	590.00	[ICRA] AA/Negative; withdrawn
INE140A07492	PP-MLD	03-Jan-19		28-Jan-20	150.00	PP-MLD [ICRA] AA/ Negative; withdrawn

*Source: Company; *Above ISIN was prepaid by the company*

Annexure-2: List of entities considered for consolidated analysis

Company Name	Ownership	Consolidation Approach
PHL Fininvest Private Limited	100%	Limited Consolidation
Searchlight Health Private Limited	51%	Full Consolidation
Piramal International	100%	Full Consolidation
Piramal Holdings (Suisse) SA	100%	Full Consolidation
Piramal Dutch Holdings N.V.	100%	Full Consolidation
Piramal Critical Care Italia, SPA	100%	Full Consolidation
Piramal Critical Care Deutschland GmbH	100%	Full Consolidation
Piramal Critical Care B.V.	100%	Full Consolidation
Piramal Healthcare (Canada) Limited	100%	Full Consolidation
Piramal Critical Care Limited	100%	Full Consolidation
Piramal Critical Care South Africa (Pty) Ltd	100%	Full Consolidation
Piramal Critical Care Pty. Ltd.	100%	Full Consolidation
Piramal Healthcare UK Limited	100%	Full Consolidation
Piramal Healthcare Pension Trustees Limited	100%	Full Consolidation
Piramal Healthcare Inc.	100%	Full Consolidation
Piramal Critical Care Inc.	100%	Full Consolidation
Piramal Pharma Inc.	100%	Full Consolidation
PEL Pharma Inc.	100%	Full Consolidation
Piramal Pharma Solutions Inc.	100%	Full Consolidation
Ash Stevens LLC	100%	Full Consolidation
Piramal Dutch IM Holdco B.V.	100%	Full Consolidation
PEL-DRG Dutch Holdco B.V.	100%	Full Consolidation
Piramal Fund Management Private Limited	100%	Full Consolidation
Indiareit Investment Management Company	100%	Full Consolidation
Piramal Asset Management Private Limited	100%	Full Consolidation
Piramal Capital & Housing Finance Limited	100%	Limited Consolidation
Piramal Investment Advisory Services Private Limited	100%	Full Consolidation
Piramal Investment Advisory Services Private Limited	100%	Full Consolidation
Piramal Investment Opportunities Fund	100%	Full Consolidation
Piramal Systems & Technologies Private Limited	100%	Full Consolidation
Piramal Technologies SA	100%	Full Consolidation
PEL Finhold Private Limited	100%	Limited Consolidation
Piramal Consumer Products Private Limited	100%	Full Consolidation
Piramal Securities Limited	100%	Full Consolidation
Piramal Asset Management Private Limited (Singapore)	100%	Full Consolidation
Piramal Pharma Solutions BV	100%	Full Consolidation
Piramal Capital International Limited	100%	Full Consolidation
Piramal Pharma Limited	100%	Full Consolidation
List of Joint Ventures		
Convergence Chemicals Private Limited	51%	Equity Method
India Resurgence ARC Private Limited	50%	Equity Method
India Resurgence Asset Management Business Private Limited	50%	Equity Method
Asset Resurgence Mauritius Manager	50%	Equity Method
Piramal Ivanhoe Residential Equity Fund 1	50%	Equity Method
India Resurgence Fund - Scheme 2	50%	Equity Method
India Resurgence ARC trust I	50%	Equity Method
Piramal Structured Credit Opportunities Fund	25%	Equity Method
Shrilekha Business Consultancy Private Limited	74.95%	Equity Method
List of Associates		
Bluebird Aero Systems Private Limited	27.83%	Equity Method
Allergan India Private Limited	49.0%	Equity Method
Shriram Capital Limited	20.0%	Equity Method

Source: Company, Annual Report

Corrigendum

Document dated July 27, 2020 has been corrected with a revision as detailed below:

a. Revision on Page 1 – The reason for the withdrawal of CP, NCD, PP-MLD and bank loans has been specified.

Analyst Contacts

Subrata Ray
+91 22 6114 3408
subrata@icraindia.com

Gaurav Jain
+91 20 6606 9122
gaurav.jain@icraindia.com

Vanshika Gupta
+91 20 6606 9919
vanshika.gupta@icraindia.com

Relationship Contact

L Shivkumar
+91 22 24331084
shivakumar@icraindia.com

Media and Public Relations Contact

Ms. Naznin Prodhani
Tel: +91 124 4545 860
communications@icraindia.com

Helpline for business queries:

+ 91-9354738909 (open Monday to Friday, from 9:30 am to 6 pm)

info@icraindia.com

About ICRA Limited

ICRA Limited was set up in 1991 by leading financial/investment institutions, commercial banks and financial services companies as an independent and professional investment Information and Credit Rating Agency.

Today, ICRA and its subsidiaries together form the ICRA Group of Companies (Group ICRA). ICRA is a Public Limited Company, with its shares listed on the Bombay Stock Exchange and the National Stock Exchange. The international Credit Rating Agency Moody's Investors Service is ICRA's largest shareholder.

For more information, visit www.icra.in

ICRA Limited

Corporate Office
Building No. 8, 2nd Floor, Tower A; DLF Cyber City, Phase II; Gurgaon 122 002
Tel: +91 124 4545300
Email: info@icraindia.com
Website: www.icra.in

Registered Office
1105, Kailash Building, 11th Floor; 26 Kasturba Gandhi Marg; New Delhi 110001
Tel: + 91 11 2335 7940-45

Branches

Mumbai	+91 22 6169 3300
Chennai	+91 44 4596 4300
Kolkata	+91 33 7150 1100/01
Bangalore	+91 80 4922 5500/6400
Ahmedabad	+91 79 4027 1500/01
Hyderabad	+91 40 4920 0200
Pune	+91 20 2556 0194, 020 6606 9999

ICRA ratings should not be treated as recommendation to buy, sell or hold the rated debt instruments. ICRA ratings are subject to a process of surveillance, which may lead to revision in ratings. An ICRA rating is a symbolic indicator of ICRA's current opinion on the relative capability of the issuer concerned to timely service debts and obligations, with reference to the instrument rated. Please visit our website www.icra.in or contact any ICRA office for the latest information on ICRA ratings outstanding. All information contained herein has been obtained by ICRA from sources believed by it to be accurate and reliable, including the rated issuer. ICRA however has not conducted any audit of the rated issuer or of the information provided by it. While reasonable care has been taken to ensure that the information herein is true, such information is provided 'as is' without any warranty of any kind, and ICRA in particular, makes no representation or warranty, express or implied, as to the accuracy, timeliness or completeness of any such information. Also, ICRA or any of its group companies may have provided services other than rating to the issuer rated. All information contained herein must be construed solely as statements of opinion, and ICRA shall not be liable for any losses incurred by users from any use of this publication or its contents.